Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
4.010
+0.410 (11.39%)
At close: Dec 5, 2025, 4:00 PM EST
3.990
-0.020 (-0.50%)
After-hours: Dec 5, 2025, 7:57 PM EST
Quince Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 13.2 | 15.08 | 15.4 | 24.91 | 29.52 | 17.59 | |
| Research & Development | 28.61 | 18.59 | 9.25 | 25.18 | 60.8 | 61.31 | |
| Operating Expenses | 41.8 | 33.67 | 24.64 | 50.09 | 90.32 | 78.89 | |
| Operating Income | -41.8 | -33.67 | -24.64 | -50.09 | -90.32 | -78.89 | |
| Interest Expense | -0.91 | - | - | - | - | - | |
| Interest & Investment Income | 1.55 | 2.93 | 3.48 | 1.07 | 0.62 | 2.04 | |
| Currency Exchange Gain (Loss) | -0.68 | -0.68 | 0 | -0.77 | -0.25 | - | |
| Other Non Operating Income (Expenses) | -4.19 | - | - | - | - | - | |
| EBT Excluding Unusual Items | -46.03 | -31.42 | -21.16 | -49.79 | -89.95 | -76.85 | |
| Merger & Restructuring Charges | -2.5 | -2.5 | -2.5 | -1.1 | - | - | |
| Impairment of Goodwill | - | -17.13 | - | -0.83 | - | - | |
| Gain (Loss) on Sale of Assets | - | - | -0.04 | -0.09 | - | - | |
| Asset Writedown | - | - | -5.97 | -0.14 | - | - | |
| Other Unusual Items | -8.38 | -5.69 | -1.92 | - | - | - | |
| Pretax Income | -56.9 | -56.74 | -31.58 | -51.94 | -89.95 | -76.85 | |
| Income Tax Expense | 0.08 | 0.09 | -0.2 | -0.28 | - | - | |
| Net Income | -56.98 | -56.83 | -31.39 | -51.66 | -89.95 | -76.85 | |
| Net Income to Common | -56.98 | -56.83 | -31.39 | -51.66 | -89.95 | -76.85 | |
| Shares Outstanding (Basic) | 47 | 43 | 37 | 33 | 30 | 29 | |
| Shares Outstanding (Diluted) | 47 | 43 | 37 | 33 | 30 | 29 | |
| Shares Change (YoY) | 10.61% | 16.18% | 11.17% | 12.71% | 1.86% | 53.30% | |
| EPS (Basic) | -1.21 | -1.31 | -0.84 | -1.54 | -3.03 | -2.63 | |
| EPS (Diluted) | -1.21 | -1.31 | -0.84 | -1.54 | -3.03 | -2.63 | |
| Free Cash Flow | -38.98 | -32.16 | -18.45 | -44.17 | -63.11 | -50.87 | |
| Free Cash Flow Per Share | -0.83 | -0.74 | -0.50 | -1.32 | -2.12 | -1.74 | |
| EBITDA | -41.68 | -33.48 | -24.32 | -49.89 | -89.97 | -78.56 | |
| D&A For EBITDA | 0.12 | 0.19 | 0.32 | 0.2 | 0.34 | 0.33 | |
| EBIT | -41.8 | -33.67 | -24.64 | -50.09 | -90.32 | -78.89 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.